Home Cart Sign in  
Chemical Structure| 1513857-77-6 Chemical Structure| 1513857-77-6

Structure of Pemigatinib
CAS No.: 1513857-77-6

Chemical Structure| 1513857-77-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Pemigatinib, also known as INCB054828, is an orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) types 1, 2, and 3 (FGFR1/2/3), with potential antineoplastic activity. FGFR inhibitor INCB054828 binds to and inhibits FGFR1/2/3, which may result in the inhibition of FGFR1/2/3-related signal transduction pathways. This inhibits proliferation in FGFR1/2/3-overexpressing tumor cells.

Synonyms: INCB054828

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Pemigatinib

CAS No. :1513857-77-6
Formula : C24H27F2N5O4
M.W : 487.50
SMILES Code : FC1=C(C(F)=C(OC)C=C1OC)N(CC2=CNC3=NC(CN4CCOCC4)=CC3=C25)C(N5CC)=O
Synonyms :
INCB054828
MDL No. :MFCD31706227
InChI Key :HCDMJFOHIXMBOV-UHFFFAOYSA-N
Pubchem ID :86705695

Safety of Pemigatinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Pemigatinib

RTK

Isoform Comparison

Biological Activity

Target
  • FGFR2

    FGFR2, IC50:0.5 nM

  • FGFR3

    FGFR3, IC50:1.2 nM

  • FGFR4

    FGFR4, IC50:30 nM

  • FGFR1

    FGFR1, IC50:0.4 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
PDC-DUC18828 4 nM 3 days To evaluate the inhibitory effect of Pemigatinib on the growth and proliferation of FGFR2 fusion-positive ICC cell lines, results showed that Pemigatinib significantly inhibited cell proliferation at low nanomolar concentrations PMC9588766
PDO-DUC18828 2 nM 7 days To evaluate the inhibitory effect of Pemigatinib on the growth and proliferation of FGFR2 fusion-positive ICC organoids, results showed that Pemigatinib significantly inhibited organoid growth at low nanomolar concentrations PMC9588766
LX-2 cells 100 ng/mL 24 h To study the effect of FGF23 on LX-2 cells, it was found that FGF23 significantly altered the expression of 1658 genes and upregulated the expression of matrisome-related genes, promoting extracellular matrix formation. PMC11717528
Rat primary HSCs 1 ng/mL 72 h To study the effect of FGF23 on rat primary HSCs, it was found that FGF23 upregulated the expression of matrisome-related genes, promoting extracellular matrix formation. PMC11717528
primary mouse astrocytes 100 nM, 1 μM, 10 μM 24 h Pemigatinib attenuated proinflammatory signaling (Csf2, Tnf, Ccl2, Ccl5, Cxcl10). PMC9057609
primary human astrocytes 10 μM 24 h Pemigatinib treatment attenuated proinflammatory signaling but did not significantly affect cell survival. PMC9057609
ICC13-7 cells 100 nM 24 h To investigate the effect of Pemigatinib on glycolytic gene expression, results showed that Pemigatinib significantly suppressed glycolytic gene expression. PMC11076599
ICC21 cells 100 nM 24 h To investigate the effect of Pemigatinib on glycolytic gene expression, results showed that Pemigatinib significantly suppressed glycolytic gene expression. PMC11076599
NCI-H1581 lung cancer cells 100 nM 24 and 48 h Pemigatinib significantly reduced the proliferative ability of NCI-H1581 lung cancer cells, induced G1 phase cell cycle arrest, and triggered apoptosis. PMC10504800
KATO III gastric cancer cells 100 nM 24 and 48 h Pemigatinib significantly reduced the proliferative ability of KATO III gastric cancer cells, induced G1 phase cell cycle arrest, and triggered senescence. PMC10504800
RT-112 bladder cancer cells 100 nM 24 and 48 h Pemigatinib significantly reduced the proliferative ability of RT-112 bladder cancer cells, induced G1 phase cell cycle arrest, and triggered apoptosis. PMC10504800
EC PDXOs 300 nM 72 h To evaluate the effect of Pemigatinib on cell death in EC PDXOs, significant cell death was observed in models with high FGFR2c expression. PMC10703877
ICC13-7 100 nM 5 days To evaluate the sensitivity of FGFR2 fusion-positive ICC cell lines to Pemigatinib, results showed that ICC13-7 cells were highly sensitive to Pemigatinib with an IC50 of 12 nM. PMC9064956
ICC21 100 nM 5 days To evaluate the sensitivity of FGFR2 fusion-positive ICC cell lines to Pemigatinib, results showed that ICC21 cells were partially sensitive to Pemigatinib with an IC50 of ~250 nM. PMC9064956
NCI-H1581 lung cancer cells 100 nM 24 and 48 h Pemigatinib significantly reduced the proliferative ability of NCI-H1581 lung cancer cells, inducing G1 phase cell cycle arrest and apoptosis. PMC10504800
KATO III gastric cancer cells 100 nM 24 and 48 h Pemigatinib significantly reduced the proliferative ability of KATO III gastric cancer cells, inducing G1 phase cell cycle arrest and senescence. PMC10504800
RT-112 bladder cancer cells 100 nM 24 and 48 h Pemigatinib significantly reduced the proliferative ability of RT-112 bladder cancer cells, inducing G1 phase cell cycle arrest and increasing intracellular ROS production. PMC10504800

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Subcutaneous xenograft model Oral 5 mg/kg 5 days per week, continuous treatment To evaluate the inhibitory effect of Pemigatinib on the growth of FGFR2 fusion-positive ICC xenografts, results showed that Pemigatinib significantly inhibited tumor growth and prolonged the survival of mice PMC9588766
Mice Liver fibrosis model Intraperitoneal injection 0.3 mg/kg Once daily for 8 weeks To study the effect of Pemigatinib on liver fibrosis model mice, it was found that Pemigatinib significantly alleviated liver fibrosis and improved bone density and microstructure damage. PMC11717528
mice experimental autoimmune encephalomyelitis (EAE) model intranasal administration 2.5 mg/kg daily until the end of the experiment Pemigatinib had no significant effect on the EAE disease course. PMC9057609
Mice PDX models Oral 1 mg/kg Daily for 11 days To investigate the effect of Pemigatinib on glycolytic gene expression, results showed that Pemigatinib significantly suppressed glycolytic gene expression. PMC11076599
Mice EC PDX models Oral 1 mg/kg Once daily for 21 days To evaluate the tumor growth inhibition effect of Pemigatinib in EC PDX models, significant tumor growth inhibition and prolonged survival were observed in 4/5 models. PMC10703877
Mice ICC11 subcutaneous xenograft model Oral 1 mg/kg Once daily for 10 days with 4-day intervals To evaluate the in vivo efficacy of Pemigatinib in combination with Afatinib in FGFR2 fusion-positive ICC models, results showed that the combination treatment significantly inhibited tumor growth. PMC9064956

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT05287386 Advanced Non-Small Cell Lung C... More >>ancer Less << PHASE2 UNKNOWN 2025-01-21 the First Affiliated Hospital ... More >>of Xiamen University, Xiamen, Fujian, China Less <<
NCT05253807 Non-Small Cell Lung Cancer (NS... More >>CLC) Less << PHASE2 COMPLETED 2023-08-16 Valkyrie Clinical Trials, Los ... More >>Angeles, California, 90067, United States|Florida Cancer Specialists & Research Institute, Fort Myers, Florida, 33901, United States|Miami Cancer Institute, Miami, Florida, 33176, United States|Memorial Healthcare System, Pembroke Pines, Florida, 33028, United States|University of Kentucky Hospital, Lexington, Kentucky, 40536, United States|Spoknwrd Clinical Trials Inc., Easton, Pennsylvania, 18045, United States|Tennessee Oncology, Nashville, Tennessee, 37203, United States|H???PITAL NORD - CHU MARSEILLE, Marseille Cedex 5, 13385, France|Chu de Toulouse Hopital Larrey Centre de Reference Des Maladies Rares de La Peau Service de Dermatol, Toulouse, 31000, France|Zentralklinik Bad Berka Gmbh, Bad Berka, 99437, Germany|Lungenklinik Hemer, Hemer, 58675, Germany|Lki Lungenfachklinik Immenhausen, Immenhausen, 34376, Germany|University Hospital Mannheim, Mannheim, 68167, Germany|Irccs Centro Di Riferimento Oncologico, Aviano, 33081, Italy|Istituto Tumori Giovanni Paolo Ii Irccs Ospedale Oncologico Bari, Bari, 70124, Italy|Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori, Meldola, 47014, Italy|Azienda Ospedaliera Universitaria San Luigi Gonzaga Orbassano, Orbassano, 10043, Italy|Azienda Ospedaliera Di Perugia - Ospedale Santa Maria Della Misericordia, Perugia, 06132, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, 56124, Italy|Istituto Nazionale Tumori Regina Elena Irccs, Roma, 00144, Italy|Irccs Istituto Clinico Humanitas, Rozzano, 20089, Italy|Complejo Hospitalario Universitario A Coruna, A Coru?a, 15006, Spain|Hospital General Universitario Vall D Hebron, Barcelona, 08035, Spain|Hospital Clinic de Barcelona, Barcelona, 08036, Spain|Hospital de La Santa Creu I Sant Pau, Barcelona, 08041, Spain|Ico Girona Hospital Universitari de Girona Dr Josep Trueta, Girona, 17007, Spain|Hospital Universitario Ciudad de Jaen, Jaen, 23007, Spain|Ico Institut Catala D Oncologia, L'hospitalet de Llobregat, 08908, Spain|Hospital General Universitario Gregorio Maranon, Madrid, 28007, Spain|Hospital Universitario Ramon Y Cajal, Madrid, 28034, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Hospital Universitario de La Paz, Madrid, 28046, Spain|Hospital Universitario Hm Sanchinarro, Madrid, 28050, Spain|Hospital Regional Universitario de Malaga, Malaga, 29010, Spain|Hospital Universitario Virgen Macarena, Sevilla, 41009, Spain|Hospital Universitario Miguel Servet, Zaragoza, 50009, Spain Less <<
NCT03235570 Solid Tumors PHASE1 COMPLETED 2020-03-04 Aichi Cancer Center Hospital, ... More >>Aichi, 464-8681, Japan|Chiba Cancer Center, Chiba, 260-8717, Japan|National Cancer Central Hospital East, Chiba, 277-8577, Japan|Kyusyu Cancer Center, Fukuoka, 811-1395, Japan|Kanazawa University Hospital, Ishikawa, 920-8641, Japan|Kanagawa Cancer Center, Kanagawa, 241-8515, Japan|Osaka International Cancer Institute, Osaka, 541-8567, Japan|Saitama Cancer Center, Saitama, 362-0806, Japan|Hokkaido Cancer Center, Sapporo, 003-0804, Japan|Shizuoka Cancer Center, Shizuoka, 411-8777, Japan|National Cancer Central Hospital, Tokyo, 104-0045, Japan|JFCR Ariake Hospital, Tokyo, 135-8550, Japan Less <<
NCT03914794 Bladder Cancer|NMIBC|Non-Muscl... More >>e Invasive Bladder Cancer|Urothelial Carcinoma Recurrent Less << PHASE2 RECRUITING 2025-05-26 Sibley Memorial Hospital, Wash... More >>ington, District of Columbia, 20016, United States|Johns Hopkins School of Medicine - Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, 21205, United States|Associated Medical Professionals Urology, Syracuse, New York, 13210, United States|Midlantic Urology, Bala-Cynwyd, Pennsylvania, 19004, United States|Keystone Urology, Lancaster, Pennsylvania, 17604, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, 29572, United States Less <<
NCT05267106 Glioblastoma|Adult-type Diffus... More >>e Gliomas Less << PHASE2 COMPLETED 2024-12-17 Valkyrie Clinical Trials, Beve... More >>rly Hills, California, 90211, United States|City of Hope National Medical Center, Duarte, California, 91010, United States|Providence Medical Foundation, Fullerton, California, 92835, United States|Usc Norris Comprehensive Cancer Center, Los Angeles, California, 90033, United States|Stanford Neuroscience Health Center, Sacramento, California, 94304, United States|Sharp Memorial Hospital, San Diego, California, 92123, United States|University of California San Francisco, San Francisco, California, 94143, United States|Providence St Joseph Hospital Orange Center For Cancer Prevention and Treatment, Santa Monica, California, 90404, United States|Yale Cancer Center, New Haven, Connecticut, 06510-3220, United States|Baptist Md Anderson Cancer Center, Jacksonville, Florida, 32207, United States|Miami Cancer Institute, Miami, Florida, 33176, United States|Orlando Health Cancer Institute Downtown Orlando, Orlando, Florida, 32806, United States|H. Lee Moffitt Cancer Center and Research Institute Hospital, Tampa, Florida, 33612, United States|University of Illinois Hospital & Health Sciences System, Chicago, Illinois, 60612, United States|University of Iowa Hospital and Clinics, Iowa City, Iowa, 52242, United States|University Medical Center New Orleans, New Orleans, Louisiana, 70112, United States|University of Minnesota Health Clinics and Surgery Center, Minneapolis, Minnesota, 55455, United States|Northwell Health, Lake Success, New York, 11042, United States|Columbia University Irving Medical Center, New York, New York, 10032, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|East Carolina University, Greenville, North Carolina, 27834, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, 27157, United States|UC Health At Cincinnati Va Medical Center, Cincinnati, Ohio, 45229, United States|Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States|University of Pennsylvania Hospital, Philadelphia, Pennsylvania, 19104, United States|University of Pittsburgh Medical Center Health System, Pittsburgh, Pennsylvania, 15232, United States|Tennessee Oncology, Chattanooga, Tennessee, 37403, United States|Tennessee Oncology, Nashville, Tennessee, 37203, United States|Baylor University Medical Center, Dallas, Texas, 75246, United States|Houston Methodist Hospital, Houston, Texas, 77030, United States|Huntsman Cancer Institute, Salt Lake City, Utah, 84112, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, 98109, United States|Aalborg Universitets Hospital, Aalborg, 09000, Denmark|Rigshospitalet Uni of Hospital of Copenhagen, Copenhagen, 02100, Denmark|Odense University Hospital, Odense C, 05000, Denmark|Chru de Lille Hopital Claude Huriez, Lille Cedex, 59037, France|Chu Hopital de La Timone, Marseille, 13005, France|Hospital Universitaire Pitie-Salpetriere, Paris, 75013, France|Universitaire Du Cancer de Toulouse Institut Claudius Regaud Iuct-Oncopole, Toulouse, 31059, France|Universitatsklinikum Bonn Aoer, Bonn, 53127, Germany|Klinikum Der Johann Wolfgang Goethe University, Frankfurt, 60528, Germany|Universitaetsklinikum Heidelberg, Heidelberg, 69120, Germany|University Hospital Tuebingen, Tuebingen, 72076, Germany|Ospedale Bellaria, Bologna, 40139, Italy|Istituto Di Ricovero E Cura A Carattere Scientifico (Irccs) Ospedale San Raffaele, Milano, 20132, Italy|Iov - Istituto Oncologico Veneto Irccs, Padova, 35128, Italy|A.S.L. Napoli 1 Centro Ospedale Del Mare, Ponticelli, 80147, Italy|Irccs Istituto Clinico Humanitas, Rozzano, 20089, Italy|Azienda Ospedaliero Universitaria Citta Della Salute E Della Scienza, Torino, 10124, Italy|University of Tokyo Hospital, Bunkyo-ku, 113-8655, Japan|National Cancer Center Hospital, Chuo-ku, 104-0045, Japan|Kyushu University Hospital, Fukuoka-shi, 812-8582, Japan|Kyoto University Hospital, Kyoto-shi, 606-8507, Japan|Nagoya University Hospital, Nagoya-shi, 466-8560, Japan|Tohoku University Hospital, Sendai-shi, 980-8574, Japan|Netherlands Cancer Institute Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam, 1066 CX, Netherlands|Erasmus Mc Cancer Institute, Rotterdam, 3015 GD, Netherlands|Hospital Del Mar, Barcelona, 08003, Spain|Hospital General Universitario Vall D Hebron, Barcelona, 08035, Spain|Hospital Clinic Barcelona Main, Barcelona, 08036, Spain|Hospital de La Santa Creu I Sant Pau, Barcelona, 08041, Spain|Ico Girona Hospital Universitari de Girona Dr Josep Trueta, Girona, 17007, Spain|Ico Institut Catala D Oncologia, L'hospitalet de Llobregat, 08908, Spain|Hospital General Universitario Gregorio Maranon, Madrid, 28007, Spain|Hospital Universitario Ramon Y Cajal, Madrid, 28034, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Hospital Universitario Hm Sanchinarro, Madrid, 28050, Spain|Clinica Universidad de Navarra (Cun), Pamplona, 31008, Spain|Hospital General de Catalunya, Sant Cugat Del Valles, 08190, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, 41013, Spain|Hospital General Universitario de Valencia, Valencia, 46014, Spain|Addenbrooke'S Hospital, Cambridge, CB2 0QQ, United Kingdom|Velindre Cancer Centre, Cardiff, CF14 2TL, United Kingdom|St James'S University Hospital, Leeds, LS9 7TF, United Kingdom|Guys Hospital, London, SE1 9RT, United Kingdom|The Royal Marsden Nhs Foundation Trust - Sutton, London, SW3 6JJ, United Kingdom|The Royal Marsden Nhs Foundation Trust - Chelsea, London, SW36JJ, United Kingdom|The Christie Nhs Foundation Trust Uk, Manchester, M20 4BX, United Kingdom|The Clatterbridge Cancer Centre, Wirral, CH63 4JY, United Kingdom Less <<
NCT04258527 Solid Tumor PHASE1 COMPLETED 2021-03-08 Cancer Hospital of Tianjin Med... More >>ical University, Tianjin, China Less <<
NCT06300528 Relapsed or Refractory B-cell ... More >>Non-Hodgkin Lymphoma Less << PHASE2 RECRUITING 2025-12-30 Huntsman Cancer Institute at U... More >>niversity of Utah, Salt Lake City, Utah, 84112, United States Less <<
NCT05565794 Intrahepatic Cholangiocarcinom... More >>a|FGFR2 Gene Mutation|FGFR2 Gene Rearrangement|FGFR2 Gene Translocation Less << PHASE2 RECRUITING 2025-11-26 Charité - Universit?tsmedizin ... More >>Berlin, Berlin, 13353, Germany|Klinikum Esslingen, Esslingen, 73730, Germany|Krankenhaus Nordwest, Frankfurt, 60488, Germany|Klinikum Ludwigsburg, Ludwigsburg, 71640, Germany Less <<
NCT05210946 Non-Small Cell Lung Cancer UNKNOWN 2024-12-06 The First Affiliated Hospital ... More >>of Soochow University, Suzhou, China Less <<
NCT06551896 Urothelial Carcinoma|Breast Ne... More >>oplasms|Lung Cancer|Gastric Cancer|Soft Tissue Sarcoma|Other Carcinoma Less << PHASE2 NOT_YET_RECRUITING 2026-12-31 -
NCT03011372 MPN (Myeloproliferative Neopla... More >>sms) Less << PHASE2 COMPLETED 2024-10-30 Mayo Clinic Arizona, Phoenix, ... More >>Arizona, 85054, United States|City of Hope National Medical Center, Duarte, California, 91010, United States|Stanford Cancer Institute, Stanford, California, 94305, United States|Emory University - Winship Cancer Institute, Atlanta, Georgia, 30322, United States|Franciscan St. Francis Health, Indianapolis, Indiana, 46237, United States|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|Weill Cornell Medical Centers, New York, New York, 10021, United States|Md Anderson Cancer Center, Houston, Texas, 77030, United States|University of Utah, Salt Lake City, Utah, 84112, United States|Ordensklinikum Krankenhaus Der Barmherzigen Schwestern Linz, Linz, 04010, Austria|Medical University of Vienna, Wien, 01090, Austria|Iii Med. Abteilung For Hematologie and Onkologie Hanuscfhkrankenhaus, Wien, 01140, Austria|Universitair Ziekenhuis (Uz) Leuven, Leuven, 03000, Belgium|Princess Margaret Cancer Center, Toronto, Ontario, M5G 2M9, Canada|Centre Leon Berard, Lyon, 69373, France|Chu de Nice - Hospital L Archet, Nice Cedex 3, 06202, France|Hospital Saint Louis, Paris Cedex 10, 75475, France|Universitaire Du Cancer de Toulouse Institut Claudius Regaud Iuct-Oncopole, Toulouse Cedex 9, 31059, France|University Medical Center Rwth Aachen, Aachen, D-52074, Germany|Universitatsklinikum Halle (Saale), Halle, 06120, Germany|Universitatsklinikum Jena, Jena, 07740, Germany|Universitatsklinikum Leipzig, Leipzig, 04103, Germany|University Hospital Mannheim, Mannheim, 68167, Germany|Johannes Wesling Klinikum Minden, Minden, 32429, Germany|Ospedale Papa Giovanni Xxiii, Bergamo, 24127, Italy|Azienda Ospedaliero-Universitaria Careggi (Aouc), Florence, 50134, Italy|Kindai University Hospital, Osaka, 589-8511, Japan|Ntt Medical Center Tokyo, Tokyo, 141-8625, Japan|Hospital Clinico Universitario de Valencia, Valencia, 46010, Spain|Inselspital - Universitaetsspital Bern, Bern, 03010, Switzerland|Universitatsspital Zurich, Zurich, 08091, Switzerland|Guys and St Thomas Nhs Foundation Trust, London, SE1 9RT, United Kingdom|Oxford University Hospitals Nhs Foundation Trust, Oxford, OX3 7LE, United Kingdom Less <<
NCT03906357 - NO_LONGER_AVAILABLE - -
NCT03822117 Solid Tumor Malignancy PHASE2 TERMINATED 2022-03-29 Cancer Treatment Centers of Am... More >>erica, Goodyear, Arizona, 85338, United States|Mayo Clinic Hospital, Phoenix, Arizona, 85054, United States|The University of Arizona Cancer Center, Tucson, Arizona, 85724, United States|Chao Family Comprehensive Cancer Center University of California, Irvine, Orange, California, 92868, United States|Stanford Cancer Center, Palo Alto, California, 94304, United States|John Wayne Cancer Institute, Santa Monica, California, 90404, United States|St. Joseph Heritage Healthcare, Santa Rosa, California, 95403, United States|Florida Cancer Specialists & Research Institute, Fort Myers, Florida, 33901, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, 32224, United States|Florida Cancer Specialists, Saint Petersburg, Florida, 33705, United States|Florida Cancer Specialists, Tallahassee, Florida, 32308, United States|Florida Cancer Specialists, West Palm Beach, Florida, 33401, United States|Illinois Cancer Specialists, Arlington Heights, Illinois, 60005, United States|Edward H Kaplan & Associates, Skokie, Illinois, 60076, United States|Carle Cancer Center, Urbana, Illinois, 61801, United States|Cancer Treatment Centers of America, Zion, Illinois, 60099, United States|Indiana University Health - Arnett Cancer Care, Lafayette, Indiana, 47904, United States|University of Iowa, Iowa City, Iowa, 52242, United States|University of Kansas Cancer Center, Westwood, Kansas, 66205, United States|Ochsner Clinic, New Orleans, Louisiana, 70121, United States|Central Maine Medical Center, Lewiston, Maine, 04240, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Umass Memorial Medical Center, Inc., Worcester, Massachusetts, 01655, United States|Mayo Clinic Rochester, Rochester, Minnesota, 55905, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, 89148, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, 03756, United States|Summit Medical Group, Florham Park, New Jersey, 07932, United States|Winthrop University Hospital, Mineola, New York, 11501, United States|Oncology Specialists of Charlotte, Charlotte, North Carolina, 28204, United States|Duke Cancer Center, Durham, North Carolina, 27710, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, 27157, United States|Stephenson Cancer Center, Oklahoma City, Oklahoma, 73104, United States|Southwestern Regional Medical Center, Tulsa, Oklahoma, 74133, United States|Cancer Institute of Greenville Health System, Greenville, South Carolina, 29605, United States|The West Clinic Pc, Germantown, Tennessee, 38138, United States|University of Texas Southwestern Medical Center, Dallas, Texas, 75390, United States|Houston Methodist Hospital, Houston, Texas, 77030, United States|Joe Arrington Cancer Center, Lubbock, Texas, 79410, United States|Virginia Cancer Specialists, Pc, Fairfax, Virginia, 22031, United States|Virginia Oncology Associates-Lake Wright, Norfolk, Virginia, 23502, United States|Seattle Cancer Care Alliance, Seattle, Washington, 98109, United States|Multicare Institute For Research & Innovation, Tacoma, Washington, 98405, United States|West Virginia University Hospitals Inc, Morgantown, West Virginia, 26506, United States|University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, 53792, United States|The Finsen Centre National Hospital, Copenhagen, 02100, Denmark|Institut Bergonie, Bordeaux, 33000, France|CENTRE GEORGES FRAN???OIS LECLERC, Dijon Cedex, 21079, France|Centre Antoine Lacassagne, Nice, 06189, France|Hospital Saint Louis, Paris, 75010, France|A.P.H. Paris Hopital Cochin, Paris, 75014, France|Institut Universitaire Du Cancer de Toulouse Oncopole, Toulouse, 31059, France|University Medical Center Freiburg, Freiburg, 79106, Germany|University Medical Centre Hamburg-Eppendorf, Centre of Oncology, Hamburg, 20246, Germany|Universitatsklinikum Koln, Koln, 50937, Germany|University Hospital Grosshadern Munich, Munich, 81377, Germany|Universitaetsklinikum in Tubingen, Tubingen, 72076, Germany|Ha Emek Medical Center, Afula, 18101, Israel|Rambam Health Care Campus, Haifa, 3525408, Israel|Hadassah Hebrew University Medical Center Ein Karem Hadassah, Jerusalem, 90000, Israel|Rabin Medical Center - Beilinson Hospital, Petach Tikva, 4841492, Israel|Assaf Harofeh Medical Center, Zerifin, 7030000, Israel|L AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA POLICLINICO S. ORSOLA ??? MALPIGHI, Bologna, 40138, Italy|Fondazione Del Piemonte Per L Oncologia Ircc Candiolo, Candiolo, 10060, Italy|Fondazione Irccs Istituto Nazionale Dei Tumori, Milan, 20133, Italy|Istituto Nazionale Tumori Irccs Fondazione Pascale, Napoli, 80131, Italy|Istituto Nazionale Tumori Regina Elena Irccs, Roma, 00144, Italy|Centro Ricerche Cliniche Di Verona (Crc), Verona, 37134, Italy|National Hospital Organization Kyushu Cancer Center, Fukuoka, 811-1395, Japan|Kanazawa University Hospital, Ishikawa, 920-8641, Japan|Kobe University Hospital, Kobe, 650-0017, Japan|Tohoku University Hospital, Sendai-shi, 980-8574, Japan|Keio University Hospital, Shinjuku-ku, 160-8582, Japan|Shizuoka Cancer Center, Shizuoka, 411-8777, Japan|Kanagawa Cancer Center, Yokohama-shi, 241-8515, Japan|National Cancer Center, Goyang-si, 10408, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, 13620, Korea, Republic of|Severance Hospital Yonsei University Health System, Seoul, 03722, Korea, Republic of|Samsung Medical Center, Seoul, 06351, Korea, Republic of|Hospital General Universitario Vall D Hebron, Barcelona, 08035, Spain|Hospital Clinic I Provincial, Barcelona, 08036, Spain|Centro Integral Oncologico Clara Campal (Ciocc), Madrid, 28050, Spain|Hospital Regional Universitario de Malaga, Malaga, 29010, Spain|Clinica Universidad de Navarra (Cun), Pamplona, 31008, Spain|Hospital Universitario Marques de Valdecilla, Santander, 39008, Spain|Hospital Universitario Y Politcnico de La Fe, Valencia, 46026, Spain|Inselspital - Universitaetsspital Bern, Bern, 03010, Switzerland|Universitatsspital Zurich, Zuerich, 08091, Switzerland|University College London Hospitals (Uclh), London, NW1 2PG, United Kingdom|Imperial College Healthcare Nhs Trust - Hammersmith Hospital, London, W12 0HS, United Kingdom|Sarah Cannon Research Institute, London, W1G 6AD, United Kingdom Less <<
NCT05651672 Gastrointestinal Cancer PHASE2 RECRUITING 2025-12-26 Tianjin Medical University Can... More >>cer Institute & Hospital, Tianjin, Tianjin, 300060, China Less <<
NCT06022289 Solid Tumor|FGF Receptor Gene ... More >>Mutation|FGF Amplification|FGF Receptor Gene Family Rearrangement|FGF Receptor Gene Translocation Less << PHASE2 RECRUITING 2025-05-31 Tianjin Medical University Sec... More >>ond Hospital, Tianjin, Tianjin, 300211, China Less <<
NCT04256980 Cholangiocarcinoma PHASE2 COMPLETED 2023-08-31 Zhongshan Hospital Affiliated ... More >>to Fudan University, Shanghai, Shanghai, China Less <<
NCT02924376 Cholangiocarcinoma PHASE2 COMPLETED 2022-02-01 Anchorage, Alaska, United Stat... More >>es|Phoenix, Arizona, United States|Tempe, Arizona, United States|Tucson, Arizona, United States|Orange, California, United States|San Francisco, California, United States|Aurora, Colorado, United States|Denver, Colorado, United States|New Haven, Connecticut, United States|Newark, Delaware, United States|Washington, District of Columbia, United States|Gainesville, Florida, United States|Miami Beach, Florida, United States|Chicago, Illinois, United States|Evanston, Illinois, United States|Fort Wayne, Indiana, United States|Sioux City, Iowa, United States|Westwood, Kansas, United States|Louisville, Kentucky, United States|Baltimore, Maryland, United States|Ann Arbor, Michigan, United States|Detroit, Michigan, United States|Rochester, Minnesota, United States|Woodbury, Minnesota, United States|Saint Louis, Missouri, United States|Billings, Montana, United States|Omaha, Nebraska, United States|Morristown, New Jersey, United States|New York, New York, United States|Rochester, New York, United States|Charlotte, North Carolina, United States|Goldsboro, North Carolina, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Sioux Falls, South Dakota, United States|Arlington, Texas, United States|Dallas, Texas, United States|Grapevine, Texas, United States|San Antonio, Texas, United States|The Woodlands, Texas, United States|Tyler, Texas, United States|Waco, Texas, United States|Salt Lake City, Utah, United States|Fairfax, Virginia, United States|Seattle, Washington, United States|Madison, Wisconsin, United States|Brussels, Belgium|Gent, Belgium|Kortrijk, Belgium|Leuven, Belgium|Montpellier, Herault, France|Villejuif, Herault, France|Avignon, France|Clichy, France|Paris, France|Toulouse, France|Berlin, Germany|Bonn, Germany|Dresden, Germany|Hannover, Germany|Homburg, Germany|Leipzig, Germany|Mainz, Germany|Tuebingen, Germany|Jerusalem, Israel|Petach Tikva, Israel|Ramat Gan, Israel|Tel Aviv, Israel|Bari, Castellana Grotte, Italy|San Giovanni Rotondo, Foggia, Italy|Bergamo, Italy|Bologna, Italy|Candiolo, Italy|Catania, Italy|Faenza, Italy|Lecce, Italy|Meldola, Italy|Milano, Italy|Napoli, Italy|Rimini, Italy|Siena, Italy|Verona, Italy|Nagoya-shi, Aichi-Ken, Japan|Chiba-shi, Chiba-Ken, Japan|Fukuoka-shi, Fukuoka-Ken, Japan|Yokohama-shi, Kanagawa-Ken, Japan|Kyoto-shi, Kyoto-Fu, Japan|Osaka-shi, Osaka-Fu, Japan|Osakasayama-shi, Osaka-Fu, Japan|Kitaadachi, Saitama-Ken, Japan|Sunto, Shizuoka-Ken, Japan|Koto-ku, Tokyo-To, Japan|Shinjuku-ku, Tokyo-To, Japan|Goyang-si, Korea, Republic of|Seongnam-si, Korea, Republic of|Seoul, Korea, Republic of|Pamplona, Navarra, Spain|Barcelona, Spain|Girona, Spain|Madrid, Spain|Taichung, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Chiang Mai, Muang, Thailand|Khon Kaen, Muang, Thailand|Udon Thani, Muang, Thailand|Bangkok, Patumwan, Thailand|Bangkoknoi, Thailand|Cambridge, Cambridgeshire, United Kingdom|Bournemouth, Dorset, United Kingdom|Aberdeen, Grampian Region, United Kingdom|London, Greater London, United Kingdom|Cardiff, United Kingdom|Glasgow, United Kingdom|Manchester, United Kingdom|Sheffield, United Kingdom|Wirral, United Kingdom Less <<
NCT06653777 Solid Tumor, Miscellaneous PHASE2 NOT_YET_RECRUITING 2028-06-30 Institut Curie, Paris, France
NCT04294277 Urothelial Cancer PHASE2 TERMINATED 2022-11-15 ASST Papa Giovanni XXIII, Berg... More >>amo, Italy|Policlinico Sant'Orsola-Malpighi - Azienda Ospedaliero-Univeristaria di Bologna, Bologna, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy|IRCCS San Raffaele Hospital, Milano, Italy|Fondazione Policlinico Universitario A. Gemelli, IRCCS, Roma, Italy Less <<
NCT04003623 Advanced or Metastatic Solid T... More >>umors|FGFR Mutations|FGFR Translocations Less << PHASE2 TERMINATED 2020-06-12 Compassionate Cancer Care Medi... More >>cal Group, Fountain Valley, California, 92708, United States|Ocala Oncology Center, Ocala, Florida, 34474, United States|Hawaii Cancer Care, Honolulu, Hawaii, 96813, United States|Illinois Cancer Care, Peoria, Illinois, 61615, United States|FMH James M Stockman Cancer Institute, Frederick, Maryland, 21702, United States|New Jersey Cancer Care and Blood Disorders, Belleville, New Jersey, 07109, United States|TriHealth, Cincinnati, Ohio, 45220, United States|Sanford Cancer Center, Sioux Falls, South Dakota, 51704, United States|Mary Crowley Cancer Center, Dallas, Texas, 75230, United States|Oncology Consultants, Houston, Texas, 77030, United States|Utah Cancer Specialists, Salt Lake City, Utah, 84106, United States Less <<
NCT05997459 Locally Advanced Unresectable ... More >>Gastric Cancer Less << PHASE2 NOT_YET_RECRUITING 2025-03-30 Cancer center of SunYat-sen Un... More >>iversity, Guangzhou, Guangdong, 510060, China Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.05mL

0.41mL

0.21mL

10.26mL

2.05mL

1.03mL

20.51mL

4.10mL

2.05mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories